arrow
M

Mattia Lauriola

university of bologna
H指数:27
被引数:3,490

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21

Fc依赖性靶向GAS6–MERTK轴的单克隆和双特异性抗体克服了EGFR外显子19、20和21突变中的药物耐药性

2026-10-140
OA
IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy

IL-1介导的炎症促进转移性播散以及对EGFR靶向疗法的抵抗

2026-04-080
OAAI
Beyond EGFR inhibition in Head and Neck Squamous Cell Carcinoma: overcoming resistance mechanisms and novel therapeutic frontiers

头颈鳞状细胞癌中EGFR抑制之外:克服耐药机制与新型治疗前沿

2026-02-120
PRE
Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance

奥希替尼耐药和奥希替尼敏感细胞状态共存于源自奥希替尼耐药的EGFR突变NSCLC模型中

2026-01-010
OAAI
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

具有吡咯并苯并二氮杂payload的人源化间变性淋巴瘤激酶 (ALK) 定向抗体-药物偶联物在表达ALK的癌症中具有功效

2025-08-150
OA
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions (vol 31, pg 3569, 2012)

建模浸润性乳腺癌:生长因子推动HER2阳性癌前病变的进展(卷31,页3569,2012)

2025-04-110
PRE
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
2024-10-011
OAAI
Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways

Sorcin促进肿瘤细胞迁移并调控EGF依赖的EGFR信号通路

2023-07-137
OAAI
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2022-07-2757
OAAI